Agueda Rostagno

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5658389/publications.pdf

Version: 2024-02-01

49 papers	3,029 citations	186265 28 h-index	233421 45 g-index
60 all docs	60 docs citations	60 times ranked	3620 citing authors

#	Article	IF	Citations
1	Enhanced Brain Retention of AÎ²4â€x Proteoforms and its Contribution to Amyloid Deposits in Alzheimerâ€™s Disease. FASEB Journal, 2022, 36, .	0.5	0
2	The Extracellular Chaperone Clusterin in AÎ² and Nonâ€AÎ² Cerebral Amyloidoses. FASEB Journal, 2022, 36, .	0.5	0
3	Identification of Clusterin as a Major ABri- and ADan-Binding Protein Using Affinity Chromatography. Methods in Molecular Biology, 2022, 2466, 49-60.	0.9	0
4	N-terminally truncated AÎ²4-x proteoforms and their relevance for Alzheimerâ€™s pathophysiology. Translational Neurodegeneration, 2022, 11, .	8.0	7
5	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	7.9	63
6	Association of clusterin with the BRI2-derived amyloid molecules ABri and ADan. Neurobiology of Disease, 2021, 158, 105452.	4.4	5
7	Alzheimerâ€™s amyloid Î² heterogeneous species differentially affect brain endothelial cell viability, bloodâ€brain barrier integrity, and angiogenesis. Aging Cell, 2020, 19, e13258.	6.7	39
8	Ion channel formation by N-terminally truncated AÎ² (4â€“42): relevance for the pathogenesis of Alzheimer's disease. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102235.	3.3	9
9	Nrf2 activation through the PI3K/GSK-3 axis protects neuronal cells from AÎ²-mediated oxidative and metabolic damage. Alzheimer's Research and Therapy, 2020, 12, 13.	6.2	42
10	Alzheimerâ€like pathology in trisomy 21 cerebral organoids amenable to pharmacological inhibition reveals BACE2 as a geneâ€doseâ€sensitive ADâ€suppressor in human brain. Alzheimer's and Dementia, 2020, 16, e043136.	0.8	6
11	Oxidative Stress, Chronic Inflammation, and Amyloidoses. Oxidative Medicine and Cellular Longevity, 2019, 2019, 1-2.	4.0	9
12	AÎ² truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 208-225.	3.8	53
13	Unveiling Brain AÎ² Heterogeneity Through Targeted Proteomic Analysis. Methods in Molecular Biology, 2018, 1779, 23-43.	0.9	8
14	Proteomic Analysis Shows Constitutive Secretion of MIF and p53-associated Activity of COX-2 â^'/â^' Lung Fibroblasts. Genomics, Proteomics and Bioinformatics, 2017, 15, 339-351.	6.9	5
15	In vivo Differential Brain Clearance and Catabolism of Monomeric and Oligomeric Alzheimer's AÎ² protein. Frontiers in Aging Neuroscience, 2016, 8, 223.	3.4	34
16	The carbonic anhydrase inhibitor methazolamide prevents amyloid beta-induced mitochondrial dysfunction and caspase activation protecting neuronal and glial cells in vitro and in the mouse brain. Neurobiology of Disease, 2016, 86, 29-40.	4.4	73
17	Oxidative stress and mitochondria-mediated cell death mechanisms triggered by the familial Danish dementia ADan amyloid. Neurobiology of Disease, 2016, 85, 130-143.	4.4	21
18	P4-209: Methazolamide protects neuronal and glial cells from amyloid toxicity in vitro and in vivo via mitochondria-mediated mechanisms. , 2015, 11, P860-P861.		0

#	Article	IF	Citations
19	Sequential Amyloid-Î² Degradation by the Matrix Metalloproteases MMP-2 and MMP-9. Journal of Biological Chemistry, 2015, 290, 15078-15091.	3.4	107
20	Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 2457-2467.	3.8	14
21	Amyloidosis Associated with Cerebral Amyloid Angiopathy: Cell Signaling Pathways Elicited in Cerebral Endothelial Cells. Journal of Alzheimer's Disease, 2014, 42, S167-S176.	2.6	49
22	O2-12-01: MITOCHONDRIA AND DEATH RECEPTORS: KEY TARGETS FOR AMYLOID TOXICITY IN THE CEREBRAL VASCULATURE. , 2014, 10, P191-P191.		0
23	P1-109: MITOCHONDRIAL DYSFUNCTION INDUCED BY A POSTTRANSLATIONALLY MODIFIED AMYLOID LINKED TO A FAMILIAL MUTATION IN AN ALTERNATIVE MODEL OF NEURODEGENERATION. , 2014, 10, P341-P341.		0
24	Differential contribution of isoaspartate post-translational modifications to the fibrillization and toxic properties of amyloid Î² and the Asn23 Iowa mutation. Biochemical Journal, 2013, 456, 347-360.	3.7	39
25	Insights into Caspase-Mediated Apoptotic Pathways Induced by Amyloid-Î² in Cerebral Microvascular Endothelial Cells. Neurodegenerative Diseases, 2012, 10, 324-328.	1.4	41
26	Amyloid beta oligomers trigger death receptorsâ€mediated apoptosis in cerebral endothelial cells. FASEB Journal, 2012, 26, 752.8.	0.5	0
27	Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloidâ€Î² variants in cells composing the cerebral vessel walls. FASEB Journal, 2010, 24, 229-241.	0.5	74
28	Matrix Metalloproteinase 2 (MMP-2) Degrades Soluble Vasculotropic Amyloid-Î² E22Q and L34V Mutants, Delaying Their Toxicity for Human Brain Microvascular Endothelial Cells. Journal of Biological Chemistry, 2010, 285, 27144-27158.	3.4	43
29	Iowa Variant of Familial Alzheimerâ€™s Disease. American Journal of Pathology, 2010, 176, 1841-1854.	3.8	49
30	CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE. Hirosaki Medical Journal, 2010, 61, S111-S124.	1.0	16
31	Dutch and arctic mutant peptides of Î² amyloid1â€“40 differentially affect the FGF-2 pathway in brain endothelium. Experimental Cell Research, 2009, 315, 385-395.	2.6	39
32	Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathologica, 2009, 118, 115-130.	7.7	255
33	Isolation and Biochemical Characterization of Amyloid Plaques and Paired Helical Filaments. Current Protocols in Cell Biology, 2009, 44, Unit 3.33 3.33.1-33.	2.3	38
34	Preamyloid Lesions and Cerebrovascular Deposits in the Mechanism of Dementia: Lessons from Non-Î²-Amyloid Cerebral Amyloidosis. Neurodegenerative Diseases, 2008, 5, 173-175.	1.4	11
35	Preferential association of serum amyloid P component with fibrillar deposits in familial British and Danish dementias: Similarities with Alzheimer's disease. Journal of the Neurological Sciences, 2007, 257, 88-96.	0.6	24
36	Familial Danish Dementia. Journal of Biological Chemistry, 2005, 280, 36883-36894.	3.4	59

#	Article	IF	Citations
37	Systemic Catabolism of Alzheimer's AÎ²40 and AÎ²42. Journal of Biological Chemistry, 2004, 279, 45897-45908.	3.4	156
38	Cerebral Amyloid Angiopathies: A Pathologic, Biochemical, and Genetic View. Journal of Neuropathology and Experimental Neurology, 2003, 62, 885-898.	1.7	245
39	Complement Activation in Chromosome 13 Dementias. Journal of Biological Chemistry, 2002, 277, 49782-49790.	3.4	59
40	Familial Danish Dementia: A Novel Form of Cerebral Amyloidosis Associated with Deposition of Both Amyloid-Dan and Amyloid-Beta. Journal of Neuropathology and Experimental Neurology, 2002, 61, 254-267.	1.7	116
41	Tumoral non-amyloidotic monoclonal immunoglobulin light chain deposits (â€˜aggregomaâ€™): presenting feature of B-cell dyscrasia in three cases with immunohistochemical and biochemical analyses. British Journal of Haematology, 2002, 119, 62-69.	2.5	34
42	Regional Distribution of Amyloid-Bri Deposition and Its Association with Neurofibrillary Degeneration in Familial British Dementia. American Journal of Pathology, 2001, 158, 515-526.	3.8	127
43	Chromosome 13 dementia syndromes as models of neurodegeneration. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2001, 8, 277-284.	3.0	29
44	Systemic Amyloid Deposits in Familial British Dementia. Journal of Biological Chemistry, 2001, 276, 43909-43914.	3.4	73
45	Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid Î² peptides. Biochemical Journal, 2000, 348, 359-365.	3.7	219
46	Apolipoprotein J (clusterin) and Alzheimer's disease. Microscopy Research and Technique, 2000, 50, 305-315.	2.2	226
47	Apolipoprotein J (clusterin) and Alzheimer's disease. Microscopy Research and Technique, 2000, 50, 305-315.	2.2	5
48	pH-dependent fibrillogenesis of a VÎºIII Bence Jones protein. British Journal of Haematology, 1999, 107, 835-843.	2.5	31
49	A stop-codon mutation in the BRI gene associated with familial British dementia. Nature, 1999, 399, 776-781.	27.8	467